2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2730 Septic shock and inpatient palliative care utilization across hematologic malignancy subtypes: A national inpatient sample analysis

Christopher Chang Chen, DO, Anand Shah, MD2, Victor Chang, MD3
1 Rutgers New Jersey Medical School, Newark, New Jersey, United States
2 Rutgers New Jersey Medical School, Newark, New Jersey, United States
3 Rutgers New Jersey Medical School, Newark, New Jersey, United States

Background: Integrating palliative care (PC) into hematologic malignancy (HM) care remains challenging because many HMs are often treatment-responsive and transfusion needs complicate hospice transitions. Patterns of inpatient PC use in HM remain poorly defined, particularly during life-threatening complications such as septic shock. We evaluated PC use by septic shock status, variation across HM subtypes, modification by bone marrow/hematopoietic stem cell transplant (BMT/HSCT) status, and PC use among in-hospital decedents.

Methods: We queried the 2016–2022 National Inpatient Sample for adult hospitalizations involving lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), other leukemias, multiple myeloma/plasma-cell neoplasms, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). Septic shock, inpatient PC use, and BMT/HSCT status were identified using ICD-10-CM codes. Weighted analyses assessed demographic, socioeconomic, hospital, disease-specific, and acute-illness characteristics. Multivariable logistic regression adjusted for age, sex, race, payer, income quartile, cancer-excluded Charlson Comorbidity Index (CCI), HM subtype, hospital characteristics, and admission year. Interaction models evaluated whether the association between septic shock and PC differed by HM subtype and BMT/HSCT status. Estimated annual percent change (EAPC) was calculated for temporal trends. p<0.05 was considered statistically significant.

Results: We identified 994,992 unweighted (4,974,958 weighted) HM hospitalizations, including 43,271 unweighted (216,355 weighted) with septic shock. Compared with hospitalizations without septic shock, the septic-shock cohort was more often male (59.85% vs. 54.89%), had higher mean CCI (2.27 vs. 1.86), longer length of stay (14.40 vs. 7.25 days), and higher in-hospital mortality (40.44% vs. 3.81%; all p<0.001). Independent correlates of PC use included older age, later admission year, treatment at urban teaching and larger hospitals. PC use was higher with septic shock than without septic shock (27.55% vs. 7.23%; p<0.001). After adjustment, septic shock remained associated with higher odds of PC use (aOR 4.75, 95% CI 4.64–4.87; p<0.001) and an 18.63-percentage-point higher adjusted probability (25.89% vs. 7.26%; p<0.001). Overall PC use increased from 6.75% in 2016 to 9.91% in 2022. Among septic-shock hospitalizations, PC use increased from 23.61% to 30.97%, fastest in MPN (EAPC 9.93%, 95% CI 6.71–13.25; p=0.010).

The adjusted association differed significantly across HM subtypes. Septic shock was associated with higher PC use in every subtype, with the largest increases in ALL (+25.63 percentage points), CML (+21.83), and lymphoma (+21.36), and the smallest in MPN (+14.67). Among septic-shock hospitalizations, adjusted PC use was highest in ALL (35.20%) and AML (34.69%) and lowest in MPN (19.90%). BMT/HSCT status did not significantly modify the association between septic shock and PC use (p=0.445), with similar adjusted increases among non-BMT and BMT/HSCT hospitalizations (18.52 and 20.38 percentage points, respectively).

Among 53,737 unweighted (268,685 weighted) in-hospital decedents, PC use was lower with septic shock than without septic shock (46.61% vs. 56.16%; p<0.001). The adjusted inverse association was greatest in AML (−11.05 percentage points, 95% CI −13.37 to −8.73; p<0.001) and lymphoma (−9.74, 95% CI −11.35 to −8.13; p<0.001).

Conclusion: Septic shock was strongly and independently associated with inpatient PC use in HM, although the magnitude varied across malignancy subtypes, potentially reflecting differences in disease course, treatment paradigms, and prognosis. BMT/HSCT status did not materially modify this association. PC use increased over time; however, septic-shock decedents were less likely to have documented PC use despite markedly greater mortality, suggesting a potential gap or delayed integration of PC during critical illness among patients who ultimately died in the hospital. Limitations include the retrospective design, potential coding errors, and inability to establish the timing of PC. These findings highlight clinically meaningful variation in inpatient PC use across HM and support further investigation into whether PC is being integrated appropriately according to disease course and acute illness severity.

Christopher Chang Chen, DO: No relevant conflicts of interest to declare.